Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide
Language English Country United States Media print
Document type Case Reports, Journal Article
- MeSH
- Antineoplastic Agents, Alkylating therapeutic use MeSH
- Biopsy MeSH
- CD4-Positive T-Lymphocytes drug effects immunology pathology MeSH
- Leukemia, Myelomonocytic, Chronic drug therapy immunology pathology MeSH
- Cyclophosphamide therapeutic use MeSH
- Immunohistochemistry MeSH
- Lymphoma, T-Cell, Cutaneous complications drug therapy immunology pathology MeSH
- Skin immunology pathology MeSH
- Humans MeSH
- Myelodysplastic Syndromes drug therapy immunology pathology MeSH
- Skin Neoplasms drug therapy immunology pathology MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Antineoplastic Agents, Alkylating MeSH
- Cyclophosphamide MeSH
Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas. Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification. It still awaits development of more precise diagnostic criteria and optimal therapy. We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide. It seems that cyclophosphamide as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option.
References provided by Crossref.org
